KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis

KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis

  • Products Id :- GDHC010SP
  • |
  • Pages: 29
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis


This KOL Insight briefing focuses on perceptions of IL-6 inhibitors in rheumatoid arthritis (RA).

The briefing includes analysis of KOL opinion on the following topic areas-

- Current or anticipated future use of sarilumab in RA

- Current use of tocilizumab in RA

- Expected future change to sarilumab & tocilizumab use

- Comparison of sarilumab & tocilizumab clinical profile in RA

- Non-clinical differentiating factors between sarilumab & tocilizumab

- Impact of and factors contributing to sirukumab discontinuation in RA

- IL-6 inhibitors vs. JAK inhibitors in RA

- KOL awareness of olokizumab currently in development for RA

Key Highlights

- Majority of US but not EU patients have access to sarilumab, with KOLs primarily positioning sarilumab in MTX-IR patients or after anti-TNFs

- Most KOLs position tocilizumab after anti-TNFs, partly due to payer pressure, with first-line use possible in MTX-IR or ineligible patients

- In the next 12 months, most KOLs expect an increase in use of sarilumab, and a reduction in use of tocilizumab.


- The briefing is based on Sociable Pharma's analysis of primary research with our RA key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: Five Europe-based & five US-based

- Interviews performed in December 2017

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "IL-6 inhibitors in Rheumatoid Arthritis"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of rheumatoid arthritis

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Executive Summary


Research Panel Composition

Results & Implications


Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com






Rheumatoid arthritis, IL-6 inhibitors, sarilumab, tocilizumab, anti-TNFs

select a license
Single User License
USD 2500 INR 171550
Site License
USD 5000 INR 343100
Corporate User License
USD 7500 INR 514650



The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com